BIOLIFE SOLUTIONS INC (BLFS) Forecast, Price Target & Analyst Ratings
NASDAQ:BLFS • US09062W2044
19.86 USD
-0.26 (-1.29%)
At close: Mar 6, 2026
19.86 USD
0 (0%)
After Hours: 3/6/2026, 8:02:47 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOLIFE SOLUTIONS INC (BLFS).
Forecast Snapshot
Consensus Price Target
$32.87
+ 65.49% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$0.02
Revenue Estimate26.041M
ChartMill Buy Consensus
83.75%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$32.87
Upside
+ 65.49%
From current price of $19.86 to mean target of $32.87, Based on 16 analyst forecasts
Low
$30.30
Median
$32.64
High
$35.70
Price Target Revisions
1 Month
0.00%
3 Months
0.38%
Price Target Summary
16 analysts have analysed BLFS and the average price target is 32.87 USD. This implies a price increase of 65.49% is expected in the next year compared to the current price of 19.86.
The average price target has been revised upward by 0.38% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.75%
BLFS was analyzed by 16 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BLFS.
In the previous month the buy percentage consensus was at a similar level.
BLFS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-08 | Northland Capital Markets | Maintains | Outperform -> Outperform |
| 2024-12-19 | Benchmark | Reiterate | Buy -> Buy |
| 2024-12-13 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | TD Cowen | Maintains | Buy -> Buy |
| 2024-11-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-12 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-08-09 | Northland Capital Markets | Maintains | Outperform -> Outperform |
| 2024-07-17 | TD Cowen | Maintains | Buy -> Buy |
| 2024-05-13 | Benchmark | Upgrade | Hold -> Buy |
| 2024-04-04 | Jefferies | Initiate | Buy |
| 2023-08-10 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-08-09 | TD Cowen | Maintains | Outperform -> Outperform |
| 2023-08-09 | Lake Street | Maintains | Buy -> Buy |
| 2023-07-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2023-07-11 | Craig-Hallum | Initiate | Buy |
| 2023-03-17 | Stephens & Co. | Maintains | Overweight |
| 2023-03-06 | Oppenheimer | Reiterate | Outperform |
| 2022-05-10 | Keybanc | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$0.02
Revenue Estimate26.041M
Revenue Q2Q8.77%
EPS Q2Q270.03%
Number of Analysts12
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.15%
EPS (1 Month)
0.00%
EPS (3 Months)
-73.36%
Next Earnings Summary
BLFS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 0.02 USD and the consensus revenue estimate is 26.04M USD.
The next earnings revenue estimate has been revised upward by 0.15% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 68.016M -57.96% | 74.647M 9.75% | 96.214M 28.89% | 114.69M 19.20% | 135.41M 18.07% | 164.42M 21.42% | 200.57M 21.99% | 247.7M 23.50% | 310.03M 25.16% | 385.48M 24.34% | 491.19M 27.42% | |
| EBITDA YoY % growth | -4.91M 73.63% | 4.184M 185.21% | 3.606M -13.81% | 34.129M 846.45% | 45.39M 33.00% | 66.81M 47.19% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -17.205M 50.98% | -4.477M 73.98% | -1.081M 75.85% | 4.019M 471.79% | 20.378M 407.04% | 41.982M 106.02% | 45.33M 7.97% | 70.363M 55.22% | 91.471M 30.00% | 129.72M 41.82% | 189.72M 46.25% | |
| Operating Margin | -25.30% | -6.00% | -1.12% | 3.50% | 15.05% | 25.53% | 22.60% | 28.41% | 29.50% | 33.65% | 38.62% | |
| EPS YoY % growth | -1.15 28.57% | -0.51 55.65% | 0.21 141.18% | 0.15 -28.76% | 0.41 176.13% | 0.87 109.88% | 0.87 | 1.17 35.29% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.02 270.03% | 0.03 406.00% | 0.03 223.03% | 0.04 -82.38% | 0.08 379.90% | 0.09 183.33% | 0.10 215.76% | 0.11 176.32% |
| Revenue Q2Q % growth | 26.041M 8.77% | 27.732M 9.09% | 29.483M 5.05% | 30.411M 22.80% | 31.315M 20.25% | 32.677M 17.83% | 35.399M 20.07% | 36.761M 20.88% |
| EBITDA Q2Q % growth | 7.392M 4,353.01% | 8.168M 396.84% | 8.66M 115.85% | 9.137M 51.43% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 437.753K 135.94% | 1.101M 198.13% | 1.374M 1,643.82% | 1.696M 25.91% | 4.829M 1,003.13% | 5.039M 357.67% | 5.459M 297.31% | 5.669M 234.26% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
60.42%
EPS Next 5 Year
41.06%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
19.06%
Revenue Next 5 Year
20.52%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
77.39%
EBIT Next 5 Year
N/A
BIOLIFE SOLUTIONS INC / BLFS Forecast FAQ
What is the average price target for BIOLIFE SOLUTIONS INC (BLFS) stock?
16 analysts have analysed BLFS and the average price target is 32.87 USD. This implies a price increase of 65.49% is expected in the next year compared to the current price of 19.86.
Can you provide the upcoming earnings date for BIOLIFE SOLUTIONS INC?
BIOLIFE SOLUTIONS INC (BLFS) will report earnings on 2026-05-06.
Can you provide the consensus estimates for BIOLIFE SOLUTIONS INC next earnings?
The consensus EPS estimate for the next earnings of BIOLIFE SOLUTIONS INC (BLFS) is 0.02 USD and the consensus revenue estimate is 26.04M USD.
What is the number of analysts for BLFS stock?
The number of analysts covering BIOLIFE SOLUTIONS INC (BLFS) is 16.